Ventral Hernia Improvement of Treatment and Life
Launched by LINE MARKER · Mar 3, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years
- • Incisional hernia or parastomal hernia
- Exclusion Criteria:
- • - Can't understand or read Danish
About Line Marker
Line Marker is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on precision medicine, Line Marker collaborates with leading researchers and healthcare institutions to accelerate the discovery and delivery of novel therapies. The organization is committed to adhering to the highest ethical standards and regulatory requirements while fostering a patient-centric approach in all its clinical studies. By leveraging cutting-edge technology and data analytics, Line Marker aims to enhance the efficiency and effectiveness of clinical trials, ultimately improving patient outcomes and transforming the landscape of medical treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Køge, , Denmark
Patients applied
Trial Officials
Frederik Helgstrand, DMSc
Study Director
Zealand University Hospital, Køge
Line Marker, MD
Principal Investigator
Zealand University Hospital, Køge
Pernille D.K. Diasso, MD, Ph.d.
Study Director
Zealand University Hospital, Køge
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported